



Disclosures

Planners and Managers

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Faculty

Agarwal:

Consultant, Advisor, Speaker: Bayer Pharmaceuticals, Boehringer Ingelheim

Other: Alnylam, Chinook, Vertex, Intercept

Royalties: UptoDate

Aleppo:

Consultant, Advisor, Speaker: Dexcom, Insulet, Medscape

Researcher: Bayer, Fractyl, Insulet, MannKind, Tandem Diabetes

Aronne:

Stock and Stock Options: Myos Corp, ERX Pharmaceuticals

Consultant, Advisor, Speaker: Altimune, Atria, Eli Lilly

Researcher: AstraZeneca, Eli Lilly

Other: ERX Pharmaceuticals

Ballantyne:

Grant/Research Support- (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA.

Consultant- 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic.

Barb:

Consultant, Advisor, Speaker: Novo Nordisk, Boehringer Ingelheim

Other: Boehringer Ingelheim, Inventiva, Pharma

Bhatt:

Advisory Board: Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys

Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock)

Individual publicly traded stocks and stock options: Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock)

Consultant: Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene

Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial)

Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);

Researcher: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia,

NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;

Royalties: Elsevier (Editor, Braunwald's Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo.

Burka:

Dr. Burka has no relevant financial relationship(s) with ineligible companies to disclose.

Dagogo-Jack:

Consultant, Advisor, Speaker: Merck, Medtronic

Other: Jana Care, Aerami Therapeutics

Eckel:

Consultant, Advisor, Speaker: Amgen, Better Co., 89bio, Ionis, Novo Nordisk, Madrigal

Other: Arrowhead, Regeneron

Ferdinand:

Researcher: Boehringer Ingelheim, Lilly, Janssen, Novartis

Consultant, Advisor, Speaker: Medtronic

Florez:

Researcher: Novo Nordisk

Gulati:

Consultant, Advisor, Speaker: Medtronic, Esperion, Novartis

LaFata:

Dr. LaFata has no relevant financial relationship(s) with ineligible companies to disclose.

Libby:

Consultant (unpaid) to, or involved in clinical trials for: Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer, and Sanofi-Regeneron.

Scientific advisory boards: Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Therapeutics, and XBiotech, Inc.

Laboratory has received research funding: Novartis, Novo Nordisk and Genentech.

Board of Directors of XBiotech, Inc.

Financial interest in Xbiotech, TenSixteen Bio, and in Soley Therapeutics

Funding support from the National Heart, Lung, and Blood Institute (1R01HL134892, 1R01HL163099-01, R01AG063839, R01HL151627, R01HL157073, R01HL166538), the RRM Charitable Fund, and the Simard Fund

Michos:

Consultant, Advisor, Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novo Nordisk, Novartis, New Amsterdam, Pfizer

Morris:

Researcher: Esperion

Ndumele:

Dr. Ndumele has no relevant financial relationship(s) with ineligible companies to disclose.

Peters:

Advisory Board: Abbott Diabetes Care, Medscape, Vertex, Zealand

Research Support: Abbott Diabetes Care, Dexcom, Insulet

Stock Options: Omada Health

Shapiro:

Consultant, Advisor, Speaker: Amgen, Tourmaline, Arrowhead, Ionis, Novartis, New Amsterdam, Merck, Regeneron

Shiffman:

Researcher: Bio89, CymaBay, Durect, Galectin, HepQuant, Hanmi

Consultant, Advisor, Speaker: CymaBay, HepQuant

Shubrook:

Consultant, Advisor, Speaker: Abbott, Bayer, Eli Lilly, Madrigal, Nevro, Novo Nordisk

Somers:

Consultant: Jazz Pharmaceutical, Lilly, Know Labs, Axsome, Apnimed

Advisor: Sleep Number

Stefanidis:

Consultant, Advisor, Speaker: Johnson and Johnson, Applied medical

Researcher: Beckton Dickinson, Intuitive surgical

Taub:

Consultant, Advisor, Speaker : Amgen, Boehringer Ingelheim/Lilly, Novartis, Novo Nordisk, Esperion, Medtronic, Edwards, Sanofi